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Abstract
Background: Although promising for graft-versus-host disease (GvHD) treatment, MSC therapy still faces important
challenges. For instance, increasing MSC migratory capacity as well as potentializing immune response suppression
are of interest. For GvHD management, preventing opportunistic infections is also a valuable strategy, since
immunocompromised patients are easy targets for infections. LL-37 is a host defense peptide (HDP) that has been
deeply investigated due to its immunomodulatory function. In this scenario, the combination of MSC and LL-37
may result in a robust combination to be clinically used.
Methods: In the present study, the effects of LL-37 upon the proliferation and migratory capacity of human
placenta-derived MSCs (pMSCs) were assessed by MTT and wound scratch assays. The influence of LL-37 over the
immunosuppressive function of pMSCs was then investigated using CFSE cell division kit. Flow cytometry and
real-time PCR were used to investigate the molecular mechanisms involved in the effects observed.
Results: LL-37 had no detrimental effects over MSC proliferation and viability, as assessed by MTT assay. Moreover,
the peptide promoted increased migratory behavior of pMSCs and enhanced their immunomodulatory function
over activated human PBMCs. Strikingly, our data shows that LL-37 treatment leads to increased TLR3 levels, as
shown by flow cytometry, and to an increased expression of factors classically related to immunosuppression,
namely IDO, IL-10, TGF-β, IL-6, and IL-1β.
Conclusions: Taken together, our observations may serve as groundwork for the development of new therapeutic
strategies based on the combined use of LL-37 and MSCs, which may provide patients not only with an enhanced
immunosuppression regime, but also with an agent to prevent opportunistic infections.
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Background
Mesenchymal stem cells (MSCs) have riveted the atten-
tion of the scientific community, due to their surprisingly
effective ability to suppress immune response. Although
not completely understood, such immunomodulatory
function of MSCs occurs mainly by secretion of soluble
factors, cell-cell contact, and induction of regulatory T
cells [1]. Due to their immune response modulation
properties, MSCs have been used in clinical settings,
especially in order to treat situations where the immune
response is exacerbated, as occurs in the graft-versus-host
disease (GvHD), a common life-threatening disorder
characterized by damage in the liver, skin, mucosa, and
gastrointestinal tract of patients who received allogeneic
hematopoietic cell transplantation [2]. In GvHD patients,
harsh immunosuppressive regimens are performed to
control the disease, though at a cost of higher frailty
against infections. Thus, relapse, lethal GvHD, and oppor-
tunistic infections are the main causes of death of patients
following transplantation [3].
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Despite promising, the results obtained by MSC treat-
ment of GvHD are still heterogeneous, and there is
much room for improvement [4, 5]. Moreover, the cost
and time required for expansion of MSCs prior to clin-
ical use constitute an important limitation to a more
widespread clinical application of MSCs [6]. Therefore,
it is imperative to search for strategies aiming at boost-
ing the immunosuppressive role of MSCs while facilitat-
ing their production and engraftment. In this sense,
research focused on MSC licensing is currently under-
way, with some exciting results in mice, in which MSCs’
immunosuppresive functions are enhanced if cells are
presented with interferon gamma (INF-ɣ) prior to GvHD
treatment [7, 8]. However, the same observations were
not reproduced when human MSCs were INF-γ licensed
and used to control T cell proliferation in vitro [9] and
to control immune response in vivo [10].
An additional strategy under investigation, aiming to
enhance MSC-mediated effects is the modulation of
Toll-like receptors (TLRs), since priming of MSCs with
specific TLR agonists efficiently directs these cells to
take an anti-inflammatory or pro-inflammatory pheno-
type, therefore importantly influencing MSCsʼ immuno-
suppressive potential [11, 12]. Less innovative, but still
relatively successful, is the combination of MSC therapy
with immunosuppressants. So far, achieved results are
conflicting, being that some authors show benefits when
following this formula, while others emphasize that im-
munosuppressants actually compromise MSC function
and antagonize their immunomodulatory effects [13–
16].
Currently, several host defense peptides (HDPs) have
been investigated due to their immunomodulatory
functions [17]. Although several classes of HDPs exist,
cathelicidin LL-37 (LL-37) is the sole member of the
cathelicidin family found in humans [18]. First described
in leukocytes [19], LL-37 can in fact be found in various
cell types, tissues, and body fluids, including bone mar-
row [20], saliva [21], amniotic fluid [22], lung epithelia
[23], breast milk [24], and others. Despite being harmless
to human cells in low concentrations, LL-37 exhibits
clear antimicrobial activities against several opportunis-
tic pathogens [18, 25], being capable of causing mem-
brane disruption [26]. Interestingly, LL-37 production
constitutes a mechanism by which MSCs exert their
antimicrobial activity [27]. In human cells, it has been
shown that LL-37 mediates important signaling by bind-
ing to the formyl peptide receptor-like 1 (FPRL1) [28],
purinergic receptor P2X7 (P2X7) [29], and epidermal
growth factor receptor (EGFR) [30]. LL-37 also demon-
strated the capability of modulating pathways related to
immune and inflammatory response, stimulating both
pro-inflammatory and anti-inflammatory response, de-
pending on the environmental and cellular context in
which it is exposed [26]. Among described events lead by
LL-37 chemoattraction of T cells, mononuclear cells, and
neutrophils [31, 32]; antagonism of pro-inflammatory
cytokine production [33, 34]; and induction of strong anti-
inflammatory response through modulation of TLR
signaling and stimulation of interleukin 10 (IL-10) produc-
tion [35, 36] are of note.
Given the LL-37 protective effects against the oppor-
tunistic microorganisms and its broad-spectrum action
on immune response modulation, here we evaluated if
this peptide could exert any impact on the immunosup-
pressive function of human placental-derived MSCs
(pMSCs). Our data shows that, when in contact with
LL-37, MSCs preserve their viability and proliferation
properties, but also induce higher suppression of T cell
activation, measured as proliferation following mitogenic
stimulation. This effect is not observed when MSCs are
pretreated with LL-37, therefore not working as a licens-
ing agent, but as an adjuvant. Nevertheless, LL-37 action
is not related to any direct effect over T cells, since
LL-37 actually enhances T cell proliferation in the absence
of MSCs. Strikingly, LL-37 induced MSCs to express the
anti-inflammatory factors indoleamine 2,3-dioxygenase
(IDO), IL-10 and transforming growth factor beta (TGF-β)
and lead to an increased TLR3 expression, which could ex-
plain, at least in part, our observations. To the best of our
knowledge, this is the first demonstration that LL-37 in
fact boosts human MSC immunosuppressive effect.
Methods
Isolation and culture
Placentas (n = 3) were collected from normal full-term
pregnancies following informed consent, being the pMSCs
obtained from cotyledons present toward the maternal side
of the placenta. Following isolation, the cotyledons were
washed with a solution of phosphate-buffered saline (PBS)
containing 100 U penicillin/streptomycin and cut into small
pieces. After, harvested pieces were submitted to enzymatic
digestion by incubation with 0.5% collagenase type IA
(Sigma-Aldrich, St. Louis, MO, USA) for 45 minutes. Then,
the enzyme was inactivated by Roswell Park Memorial
Institute (RPMI) medium supplemented with 5% fetal
bovine serum (FBS; HyClone, Logan, UT, USA). The ob-
tained homogenate was washed in PBS and suspended in
basal medium, composed of alpha–minimum essential
medium (α-MEM) supplemented with 15% fetal bovine
serum (FBS; HyClone, Logan, UT, USA), 2 mM glutamine,
and 100 U penicillin/streptomycin (Sigma-Aldrich, St.
Louis, MO, USA). Cells were then plated and allowed to
adhere overnight. Non-adherent cells were washed away
during medium changes. pMSCs from the fourth to sixth
passage were used for experiments. All experiments per-
formed in this study were conducted with the approval of
the Institutional Ethics Committee.
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Experimental design
Isolated pMSCs were submitted to different procedures,
as follows. Untreated pMSCs (control) received no pre-
treatment or treatment. In this group, cells were plated
and maintained in basal media during the whole experi-
ment. Pretreated pMSCs were plated on day −2 and in-
cubated with 1 or 10 μg/mL of LL-37 from day −2 to
day 0. On day 0, LL-37 was washed out three times with
PBS and cells were maintained in basal media from day
0 to the end of the experiment, being that no further
treatment with LL-37 was performed in this group.
Finally, treated pMSCs were plated on day −2 and main-
tained in basal media until day 0. On day 0, treated
pMSCs received either 1 or 10 μg/mL of LL-37, which
was maintained until the day of experiments.
LL-37 synthesis and mass spectrometry analyses
The original sequence of LL-37 was purchased from
Peptides 2.0 (Chantilly, VA, USA) and then re-suspended
in 500 μl of ultrapure water with 95% purity degree. In
order to remove impurities, LL-37 was applied onto a
reversed-phase high-performance liquid chromatography
(HPLC) column (Vydac C18 TP522; Hichrom, Reading,
UK) and eluted with a linear acetonitrile gradient (5–50%
for 15 min), at flow rate of 1 ml.min−1. Peptide elution
was monitored at 216 nm. Purified peptide was checked
by mass spectrometry (MALDI-TOF/TOF Ultraflex II;
Bruker Daltonics, Bremen, Germany).
pMSC characterization
5 × 105 pMSCs per tube were phenotypically characterized
by flow cytometry (FACSCalibur, BD Biosciences, Franklin
Lakes, NJ, USA), using the following antibodies CD105-
PerCP, CD54-PE, CD44-FITC, CD49e-PE, CD166-PE,
CD13-APC, HLA-ABC-PE, CD45-FITC, CD14-PE, CD51,
61-FITC, CD106-FITC, CD34-PerCP, CD31-FITC, and
HLA-DR-FITC (Pharmigen, BD Biosciences, Franklin
Lakes, NJ, USA). Ten thousand events were recorded for
each sample and data was analyzed using CellQuest soft-
ware (Becton Dickinson, Franklin Lakes, NJ, USA). In
addition, pMSCs were functionally characterized by multi-
potent differentiation in adipocytes and osteocytes, as pre-
viously described [37].
pMSC viability
The effect of LL-37 over pMSC growth (proliferation
and/or viability) was assessed by measuring the 3-(4.5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) dye absorbance of the cells. For this, we cultured
2 × 103 pMSCs in the following conditions: untreated
(control); pretreated (1 or 10 μg/mL of LL-37 treatment
from day −2 to day 0) or treated (1 or 10 μg/mL of
LL-37 was added in the 0 and kept until MTT assess-
ment, which occurred at days 1, 3, 5, and 7). For the
pretreatment group, LL-37 was washed out three times
with PBS at day 0. MTT assay was performed at 1, 3, 5,
and 7 days post plating. In these time points, 20 μL of
MTT (5 mg/mL) was added in each well and the plates in-
cubated for 3 h. After this period, MTT and medium were
discarded and replaced by DMSO, and the plate was ho-
mogenized for 15 minutes. The optical density was read
on a DTX 800 Series Multimode Detector (Beckman
Coulter, Brea, CA, USA) at 570 nm.
pMSCs migration
The effect of LL-37 on pMSCs migration was deter-
mined by wound scratch assay, according to Liang et al.
[38]. This assay was performed following the same de-
sign used to evaluate the effects of LL-37 in pMSCs via-
bility. In brief, 2 × 105 pMSCs were seeded in 6-well
plates and cultured until confluence (day −2). On day 0,
serum deprivation conditions were imposed and the
pMSC monolayers were gently scratched across the cen-
ter of the well using a 200 μL pipette tip. Untreated
pMSCs were kept in basal media during the whole ex-
periment. Pretreated pMSCs were incubated with 1 or
10 μg/mL of LL-37 from day −2 to day 0. Treated
pMSCs were incubated with 1 or 10 μg/mL of LL-37
from day 0 until the end of the experiment. Scratch zone
was photographed at day 0 and at 48 h and 96 h using a
Zeiss Primo Vert microscope equipped with a digital
camera (Carl Zeiss, Heidelberg, Germany). The scratch
was then measured using the ImageJ software (National
Institutes of Health, Bethesda, MD, USA).
Isolation and activation of peripheral blood mononuclear
cells (PBMCs)
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from the blood of healthy volunteers by centrifuga-
tion using Ficoll-Paque PLUS (Amersham Biosciences,
Uppsala, Sweden) and washed three times with PBS.
Isolated PBMCs were then activated with 10 μg/mL
phytohemagglutinin (PHA, Sigma-Aldrich, St. Louis,
MO, USA) and used in co-culture experiments after be-
ing stained with 2.5 μM carboxyfluorescein succinimidyl
ester (CFSE), as previously described [39].
Immunosuppression assays
The effect of LL-37 over the immunosuppressive cap-
acity of pMSCs was assessed in two conditions. First, we
tested the effect of LL-37 as an adjuvant, used directly in
the co-culture of pMSCs and CFSE-labeled, PHA-
activated PBMCs. In this scenario, 3.5 × 104 pMSCs and
3.5 × 105 PHA-activated PBMCs (1:10 ratio) were co-
cultured for 5 days, and 1 or 10 μg/mL LL-37 was added
in the first or third day of the experiment. On the fifth
day, PBMCs were collected and incubated with anti-
CD3 (APC-conjugated; Invitrogen, Waltham, MA, USA)
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for T cell proliferation assay by flow cytometry. In the
second condition, we tested the capacity of pMSCs pre-
treated with LL-37 to modulate the proliferation of
CFSE-labeled T cells. For this, pMSCs (3.5 × 104) were
cultured with 1 or 10 μg/mL LL-37 for 2 days. After this
period, the medium was discarded, pMSCs were washed
three times with PBS and co-cultured with PHA-
activated PBMCs (1:10 ratio) for 5 days. In parallel, the
effect of LL-37 on the proliferation of PHA-activated
PBMCs cultured alone was also investigated, as a con-
trol. On the fifth day of the assay, PBMCs were recov-
ered, stained with anti-CD3, so T cell proliferation could
be determined by flow cytometry.
TLR expression on pMSC
TLR3 and TLR4 expression levels of pMSCs (3.5 × 104) un-
treated and treated for 2 days with 1 μg/mL of LL-37 were
investigated via flow cytometry using monoclonal anti-
bodies (PE-conjugated; eBioscience, San Diego, CA, USA),
as previously described [40]. The same fluorochrome-
labeled isotype-matched monoclonal antibodies were used
as controls. Intracellular antibody staining was achieved
after fixation and permeabilization of the cells as indicated
by the manufacturer (cytofix/cytoperm buffers, BD
Biosciences, San Jose, CA, USA). Ten thousand events
were recorded for each sample and data was analyzed
using FlowJo software 10.0.7 (FlowJo LLC, Ashland, OR,
USA).
RNA isolation and real-time PCR
Gene expression analysis was performed in untreated
pMSCs and pMSCs treated with 1 or 10 μg/mL LL-37
for 2 days. Cells were recovered and submitted to ribo-
nucleic acid (RNA) extraction using the RNEasy Mini
Kkit, as indicated by the manufacturer (Qiagen, Valencia,
CA, USA). Briefly, after collection, 3 × 104 pMSCs were
disrupted in RLT buffer, ethanol was added and samples
were transferred to the kitʼs spin column. Total RNA
was retained in the column while contaminants were
washed away using buffer RW1 and buffer RPE. Then,
total RNA was eluted. RNA amount and quality were
determined using NanoDrop 1000 spectrophotometer
(NanoDrop, Wilmington, DE, USA) and analyzed by a
Bioanalyzer (Agilent Genomics, Santa Clara, CA, USA).
Samples with RIN 8 or higher were used for comple-
mentary DNA (cDNA) production. Total RNA was
reverse transcribed using the High Capacity cDNA Arch-
ive Kit, and real-time PCR was performed using TaqMan
probes and MasterMix (Applied BioSystems, Foster City,
CA, USA), following manufacturer’s instructions.
PCR for epidermal growth factor receptor 1 (EGFR1)
was performed using the sense primer 5′-GATACC
CAGGACCCAG-3′ and the antisense primer 5′-GCGA
CAATGAAAAACT-3′. As a control, GAPDH was
amplified using sense primer 5′-ACATCGCTCAGA
CACCATG-3′ and antisense primer 5′- TGTAGTT
GAGGTCAATGAAGGG-3′.
Real-time PCR for tumor necrosis factor (TNF)
(Hs01113624), TGF-β (Hs00998133), interleukin 6
(IL-6) (Hs00985639), IDO (Hs00984148), Galectin-1
(Hs00355202), interleukin 1 beta (IL-1β) (Hs00174097)
and IL-10 (Hs00961622) was done in duplicate and the
relative fold value obtained by the 2 –ΔΔCt method [41].
To normalize sample loading, the differences of threshold
cycles (ΔCt) were obtained by subtracting the Ct value for
the internal reference (β-actin) from the Ct values of the
evaluated genes. The median Ct values of the samples
from untreated pMSCs were used as a reference.
Statistical analysis
The results were given as mean ± SEM of independent
experiments. Statistical analysis and graph generation
were performed using Prism 5 software (GraphPad
Software Inc., San Diego, CA, USA). Statistical significance




Cultured pMSCs isolated from placental cotyledons
showed capacity for differentiation into adipocytes and
osteoblasts (data not shown). Furthermore, pMSCs
presented typical MSC immunophenotype, with positive
expression to CD13 (95.81%), CD29 (87.75%), CD44
(83.95%), CD49e (92.57%), CD73 (85.46%), CD90
(92.8%), and HLA-class I (74.06%) and lack of CD14
(0.35%), CD34 (0.6%), CD31 (2.68%), CD45 (0.61%), and
HLA-class II (2.11%) markers (Fig. 1).
LL-37 did not influence pMSC proliferation and viability
In order to assess the effects of LL-37 in pMSC prolifer-
ation and viability, we performed the MTT assay in un-
treated (control); pretreated with LL-37; or treated with
LL-37 pMSCs (Fig. 2a). No changes were observed in
pMSC viability or proliferation, regardless of the time of
evaluation, treatment regimen and concentration of
LL-37 performed (Fig. 2b).
LL37 induces pMSCs migration
The effects of LL-37 in pMSCs migration were investi-
gated by wound scratch assay in untreated (control), pre-
treated with LL-37 or treated with LL-37 pMSCs (Fig. 3a).
The pretreatment of pMSCs with 1 and 10 μg/mL of
LL-37 did not influence the migratory cells ability. How-
ever, the treatment with 1 μg/mL of LL-37 enhanced the
migratory potential of pMSCs after 48 h (p = 0.005)
(Fig. 3b) and 96 h (p = 0.007) of culture (Fig. 3c). Likewise,
an increased migratory behavior of pMSCs was detected
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in cells treated with 10 μg/mL of LL-37 for 48 (p = 0.02)
and 96 h (p = 0.009).
LL-37 enhances pMSCs immunomodulation
Proliferation of activated T cells was inhibited by pMSCs
obtained from placental cotyledons in a dose-dependent
manner (Fig. 4a). To evaluate the effects of LL-37 in this
pMSCs property, we initially investigated if the pre-
treatment of pMSCs with LL-37 could influence the
immunomodulatory function of these cells (Fig. 4b).
Data indicates that the culture of pMSCs with LL-37 for
2 days did not modify the capacity of these cells to con-
trol T cell proliferation in the absence of LL-37. Another
investigation made was if the LL-37 would act as an
adjuvant and exert any effect over the pMSCs-PBMCs
co-culture. Interestingly, when added on the third day of
culture, regardless if at 1 or 10 μg/mL, LL-37 enhanced the
anti-proliferative effects of pMSCs on T cells (p = 0.001
Fig. 1 Characterization of pMSCs. Flow cytometry histograms show the expression levels of CD73, CD29, CD90, CD44, CD49e, CD13, HLA-ABC,
CD45, CD34, CD31, CD14, and HLA-DR on pMSCs. Representative results from three independent experiments (biological replicates) are shown
Fig. 2 pMSCs proliferation and viability. a Experimental schedule. BM basal medium. b Untreated pMSCs, pMSCs pretreated with 1 ug/mL of
LL-37 (1 LL37pre) or with 10 ug/mL of LL-37 (10 LL37pre), and pMSCs treated with 1 ug/mL LL-37 (1 LL371d) or with 10 ug/mL of LL-37 (10 LL371d)
were cultured for 7 days, then cell proliferation/viability was assessed by MTT. There was no difference of proliferation/viability among groups.
Values represent the means ± SEM. Three independent experiments (biological replicates) were performed. LL-37 cathelicidin LL-3. pMSCs human
placenta-derived MSCs
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Fig. 3 (See legend on next page.)
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and p = 0.007, respectively). Although not statistically sig-
nificant, the addition of 10 μg/mL LL-37 on the first day of
the culture slightly reduced the proliferation of T cells in
approximately 20% (p = 0.059), compared to untreated
pMSCs (Fig. 4c). In order to investigate if the effect ob-
served could be the result of direct immunosuppressive ac-
tion of LL-37 on PBMCs, we added LL-37 in the culture of
activated PBMCs alone. Surprisingly, the addition of 1 and
10 μg/mL LL-37 in the first day of culture in fact enhanced
T cell proliferation (p = 0.01 and p = 0.04, respectively).
Likewise, treatment of PBMCs with 10 μg/mL LL-37 in the
third day of culture also increased T cell proliferation
(p = 0.002) (Fig. 4d).
LL-37 induces overexpression of TLR3 on pMSCs
In order to investigate a possible mechanism by which
LL-37 boosted pMSC immunosuppressive behavior,
pMSC expression of TLR3 and TLR4 were assessed by
(See figure on previous page.)
Fig. 3 LL-37 induces pMSCs migration. a Wound scratch assay for untreated pMSCs; pretreated with LL-37; or treated with LL-37. Confluent cells
in medium were wounded by a scratch with a pipette tip, and cell migration was monitored under the microscope. Representative results
from three experiments (biological replicates) are shown. Quantitative analysis of wound-induced migration assay after 2 days (b) and 4 days (c).
Results are presented as mean ± SEM of three experiments (biological replicates). *p <0.05. **p <0.01. LL-37 cathelicidin LL-3. pMSCs human
placenta-derived MSCs
Fig. 4 LL-37 enhances pMSCs immunomodulation. a pMSCs were co-cultured with PHA-activated PBMCs in different ratios and T cell proliferation
determined for flow cytometry after 5 days. pMSCs inhibited T cell proliferative response in a dose-dependent manner. b The immunosuppressive
capacity of pMSCs is not influenced by the pretreatment with LL-37 (1 LL37pre and 10 LL37pre). c pMSCs were co-cultured for 5 days with
PHA-activated PBMCs and LL-37 was added in the first (1 LL371d and 10 LL371d) or in the third (1 LL373d and 10 LL373d) day of culture. LL-37 enhanced
the anti-proliferative effects of pMSCs on T cells. d PHA-activated PBMCs were cultured for 5 days, LL-37 being added in the first (1 LL371d and 10
LL371d) or third (1 LL373d and 10 LL373d) day of culture. LL-37 increased T cell proliferation. pMSCs and PBMCs from three healthy volunteers were used
in the experiments. Results are presented as mean ± SEM. *p <0.05. **p <0.01. LL-37 cathelicidin LL-3, pMSCs human placenta-derived MSCs
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flow cytometry in pMSC treated with LL-37. Compared
to untreated control, the peptide did not modify TLR4
expression on treated pMSCs, but induced an increased
expression of TLR3 in these cells (p = 0.04) (Fig. 5).
pMSCs express EGFR1 and produce anti-inflammatory
factors in response to LL37 stimulation
Expression of EGFR1 was assessed in untreated pMSCs,
as well as in pMSCs treated with 1 and 10 μg/mL of
LL-37 for 2 days. Data shows that pMSCs express
EGFR1 in all conditions (Fig. 6a). Real-time PCR re-
vealed that transcript levels of IL-1β (p = 0.03), IL-6
(p = 0.007), IL-10 (p = 0.008), TGF-β (p = 0.02), and
IDO (p = 0.004) were all significantly increased in pMSCs
treated with 10 μg/mL of LL-37 (Fig. 6b). Although not
statistically significant, the treatment of pMSCs with
LL-37 increased the levels of galectin-1 transcript in
50% (p = 0.058), compared to untreated pMSCs. TNF
expression was not disturbed by LL-37.
Discussion
The present work shows that LL-37 does not comprom-
ise pMSC viability and proliferation, but increases their
migratory behavior and boosts the capacity of these cells
to control T cell proliferation following mitogenic stimu-
lation. Furthermore, we demonstrated that LL-37 modu-
lates TLR3 expression on pMSCs and induces high
transcript levels of several anti-inflammatory factors that
may compose some of the mechanisms by which MSCs
suppress T cell responses. Our data builds on a conflict-
ing literature, which reports contrasting effects of LL-37
regarding the protection or induction of cell apoptosis, de-
pending on the cell type [26, 33]. Using 1 and 10 μg/mL
of LL-37, we demonstrated that this peptide exerts no ef-
fect in pMSC viability. Likewise, Yang et al. [42], found no
effect of LL-37 over MSC viability, but actually showed
that LL-37 stimulates the proliferation of adipose-derived
MSCs, under serum deprivation conditions. In order to
simulate a physiological milieu, the effects of LL-37 were
evaluated in culture medium supplemented with FBS,
wherein this peptide did not affect the pMSCs prolifera-
tion. Considering that the immunosuppressive effect of
MSCs is dose-dependent, the increase of MSCs prolifera-
tion could positively influence the cells’ immunoregulatory
function. Nevertheless, we were able to detect such effect
of LL-37 over pMSC immunoregulatory function, regard-
less of any detected proliferative role of this peptide.
Among the several functions of LL-37 in the immune
response, this peptide may promote cell migration, as
demonstrated on neutrophils [43] and mast cells [44].
This effect is of interest in the context of MSC therapy.
In fact, the inefficient migratory capacity of MSCs is
considered an important factor to be overcome in order
to ensure the success in the clinical application of these
cells, as discussed by [45–47]. Our data shown that
pMSCs express EGFR, a receptor to LL-37 that controls
MSCs migration [48, 49]. The demonstration that LL-37
acts on MSC migration has been revealed in a mice
model of ovarian cancer, where LL-37 neutralization re-
duced the engraftment of MSCs in the tumor and lead
to the inhibition of cancer progression [36]. In addition,
it was shown that EGR1 [42] and TLR3 [50] are critical
factors involved in MSC migration stimulated by LL-37.
Interestingly, LL-37 is able to directly promote TLR3 sig-
naling [51, 52] and this effect has been assessed in vitro
by the detection of IL-6 [51, 53, 54]. Our findings are in
line with these observations, being that pMSCs treat-
ment with LL-37 enhanced the migratory capacity of
these cells, induced high expression of TLR3 and
increased IL-6 levels. However, it is important to
emphasize that this effect appears to be dependent on
the continuous LL-37 stimulus, since no pMSC migra-
tion effects were observed when these cells were pre-
treated with this peptide.
Fig. 5 TLR3 and TLR4 expression on pMSCs. pMSCs were cultured in the presence or absence of LL-37 for 2 days. Expression of TLR3 (a) and
TLR4 (b) was determined by flow cytometry. LL-37 induced TLR3 expression on pMSCs but had no effect on TLR4 expression. Results are
presented as mean ± SEM of three experiments using three different pMSC donors. LL-37 cathelicidin LL-3, 7, pMSCs human placenta-derived MSCs,
TLR Toll-like receptor
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Besides contributing for MSC migration, it has been
described that TLR3 is capable of polarizing MSCs to-
ward an anti-inflammatory phenotype with enhanced
immunosuppressive capacity [11, 12]. According to our
data, LL-37 treatment of MSCs induced TLR3 signaling
and boosted the capacity of these cells to control T cell
proliferation. In order to dissect this effect, we investi-
gated if this event could be derived from a direct sup-
pressive effect of LL-37 on T cells. Surprisingly, the
addition of this peptide to the culture of PHA-activated
PBMCs enhanced T cell proliferation. It is important to
emphasize the possibility that this pronounced effect of
LL-37 on T cell proliferation may work as a double-edged
sword, demanding a potent suppressive effect of pMSCs.
In this sense, we demonstrated that LL-37 stimulates the
overexpression of a broad arsenal of factors described to
exert central effects on MSC-mediated immunomodula-
tion, such as IL-10 [55], IL-1β [56], IDO [57], and TGF-β
[58]. Once again, we underscore that the pronounced
pMSC-suppressive effect over T cell proliferation was only
seen when LL-37 was added directly to the co-culture sys-
tem. Pretreatment of pMSCs with LL-37 was not suffi-
cient to improve the suppressive potential of these cells
on a longer observation period (5 days).
The literature reveals other important roles attributed
to LL-37. For instance, this peptide appears to exert a
protective function in MSCs against lipopolysaccharide
(LPS) pro-inflammatory stimuli [50]. This observation
is particularly relevant, given that LPS can bind to
TLR4 on the surface of MSCs and polarize these cells
to a pro-inflammatory phenotype, abolishing their po-
tential in control T cell response in vitro and, more im-
portantly, in vivo, which could explain, at least in part,
why there are responders and non-responders in MSC
therapies [12].
Conclusions
Our data demonstrates that LL-37 modulates TLR3 ex-
pression, promotes higher levels of anti-inflammatory
factors, and boosts the suppressive function of pMSCs
over stimulated T cells. The positive results constitute
important proof of concept, which stimulate further
studies in the in vivo scenario, in order to investigate
the effects of LL-37 in this complex and more realistic
context. These results may also be of great relevance
and open the possibility for a new therapeutic strategy
for a highly efficient MSC-based therapy. More inter-
estingly, in addition to boosting the immunossupressive
and migratory potential of pMSCs, LL-37 may offer
protection against opportunist microorganisms, ensur-
ing the maintenance of MSCs in their highest anti-
inflammatory state.
Fig. 6 Gene expression analysis of selected transcripts. pMSCs were cultured in the presence or absence of LL-37 for 2 days, and profiled by real-time
PCR according to (a) LL-37 receptors (EGFR and FPRL-1) and (b) pro-inflammatory and anti-inflammatory factors (IL-10, IDO, TGF-β, Galectin-1, IL-6,
IL-1β, and TNF). The relative fold values were obtained by the 2 −ΔΔCt method, using the median Ct value of untreated MSCs as a reference. Results
are presented as mean of three experiments (biological replicates). *p <0.05. **p <0.01. EGFR1 epidermal growth factor receptor 1, IDO indoleamine
2,3-dioxygenase, IL-10 interleukin 10, IL-1β1 interleukin 1 beta, IL-6 interleukin 6, pMSCs human placenta-derived MSCs, TNF tumor necrosis factor
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